Date: 2017-01-17
Type of information: Nomination
Compound: chief medical officer
Company: Galapagos (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 17, 2017, Galapagos announced the appointment of Dr. Walid Abi-Saab to the role of chief medical officer, beginning on 1 March 2017. The chief medical officer will be a member of the executive committee and drive the overall medical strategy of the company. The CMO has responsibility for late stage clinical development and operations, medical and regulatory affairs, and safety. Previously, Walid Abi-Saab was with Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories, and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, Walid was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program. Walid holds an MD degree from Université Saint Joseph in Beirut, Lebanon. He completed a Psychiatry residency training and a Neuroscience Research Fellowship at Yale University Medical School in New Haven, Connecticut.
Financial terms:
Latest news:
Is general: Yes
